清肝降压胶囊控制早期原发性开角型青光眼患者眼压的临床观察

Clinical study on treating early primary open-angle glaucoma with Qingganjiangya Capsule

目的探讨清肝降压胶囊控制早期原发性开角型青光眼(肝火亢盛、肝肾阴虚型)患者眼内压的临床疗效。方法将符合纳入标准的35例(61只眼)早期原发性开角型青光眼患者,随机分为治疗组19例(31只眼)和对照组16例(30只眼)。治疗组给予清肝降压胶囊并维持原有西医治疗,对照组仅维持原有西医治疗,疗程均为28 d。观察治疗前后患者的眼压、视力、血压、中医症候等情况。结果治疗前治疗组和对照组眼压分别为(23.68±1.89)mm Hg(1 mm Hg=0.133 kPa)和(23.74±1.46)mm Hg,治疗后治疗组和对照组眼压分别为(21.25±3.23)mm Hg和(23.20±1.93)mm Hg。经治疗后治疗组眼压下降,中医证候明显改善,与对照组相比,差异有统计学意义(P<0.01)。2组治疗后视力、血压无明显变化,前后差异无统计学意义(P>0.05)。结论清肝降压胶囊对早期原发性开角型青光眼患者有控制眼压、改善中医证候的作用。

OBJECTIVE To study the clinical effectiveness of Qinggan Jiangya Capsule in the treatment of early primary open-angle glaucoma. METHODS Thirty-five patients （61 eyes）with early primary open-angle glaucoma were randomly divided into Qinggan Jiangya Capsule treatment group （19 cases, 31 eyes ） and control group （16 cases, 30 eyes）. Each group was given the corresponding medicine treatment and both groups were treated 28 days.Intraocular pressure （IOP）, visual acuity,blood pressure and TCM symptoms before and after the treatment were observed. RESULTS Before treament the IOP of treatment group and control group were （23.68±1.89） mm Hg and （23.74±1.46） mm Hg, after treament the IOP of treatment group and control group were （21.25±3.23） mm Hg and （23.20±1.93） mm Hg. After treatment, the IOP decrease in treatment group was marker than in control group, there was statistical significance. Visual acuity and blood pressure were not significant different among groups after treatment （P〉0.05）. CONCLUSIONS In treating early primary open-angle glaucoma Qinggan Jiangya Capsule could decrease the IOP and improve TCM symptoms.